38 results
8-K
EX-10.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
29 May 24
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7:00am
reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates … Union General Data Protection Regulation (“GDPR”) (EU 2016/679) (collectively, “Privacy Laws”); (ii) the Company and the Subsidiaries have in place
8-K
EX-10.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
17 Nov 23
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its
424B4
RVPH
Reviva Pharmaceuticals Holdings Inc.
18 Oct 22
Prospectus supplement with pricing info
7:01am
, there are complex regulatory, tax, labor and other legal requirements imposed by both the European Union and many of the individual countries in Europe
8-K
EX-10.1
vqo e0hwfi
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.2
ximip
7 Sep 22
Entry into a Material Definitive Agreement
4:18pm
S-3
EX-1.2
ha6ozruh98
26 Jan 22
Shelf registration
4:15pm
424B4
gfvomzh9
28 May 21
Prospectus supplement with pricing info
4:06pm
424B4
0mstdnlxrtqzvdfvlj
17 May 21
Prospectus supplement with pricing info
12:00am
POS AM
8dvj irkrvvhx9py6z
12 May 21
Prospectus update (post-effective amendment)
4:34pm